Key result
Among 60 patients receiving new oral anticoagulants before atrial flutter ablation, there were 4 cases (6.7%) of postprocedural minor bleeding and no major bleeding events.
Why the study?
Are new oral anticoagulants safe for periprocedural anticoagulation in patients undergoing atrial flutter ablation?
Observational (n=60)
Yes
Are new oral anticoagulants safe for periprocedural anticoagulation in patients undergoing atrial flutter ablation?
New oral anticoagulants (dabigatran and rivaroxaban) appear safe for periprocedural anticoagulation in patients undergoing atrial flutter ablation, with no major bleeding reported.
May support NOAC use before atrial flutter ablation; hypothesis-generating and requires randomized confirmation before practice change.
AIM: Atrial flutter (AFL) ablation requires optimal periprocedural anticoagulation in order to minimize thromboembolic events/bleeding risk. This study describes the characteristics of patients receiving new oral anticoagulants before AFL ablation and assesses complications. METHODS: This multicenter, retrospective study reports ischemic and hemorrhagic predischarge, postprocedural complications. RESULTS: We evaluated 60 patients (62.3% male; mean age: 69.2 ± 9.7 years; CHA2DS2-VASc score: 2.44 ± 1.46, HAS-BLED score: 1.14 ± 0.7). Twenty-one (35.0%) and 23 patients (38.3%) received twice-daily dabigatran 110 or 150 mg; 16 patients (26.6%) received once-daily rivaroxaban (15 mg [n = 5] or 20 mg [n = 11]). Four cases of postprocedural minor bleeding were reported. CONCLUSION: This is the first study assessing new oral anticoagulants for periprocedural anticoagulation, specifically in patients undergoing AFL ablation. No major bleeding was reported. Further prospective investigation is warranted.
No takes yet. Share an insight, caveat, or question.
Amara et al. (2014) conducted an observational in Atrial flutter (n=60). New oral anticoagulants (dabigatran or rivaroxaban) was evaluated on Ischemic and hemorrhagic predischarge, postprocedural complications. Among 60 patients receiving new oral anticoagulants before atrial flutter ablation, there were 4 cases (6.7%) of postprocedural minor bleeding and no major bleeding events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: